Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fadi El Karak

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Expert Opinion on Pharmacotherapy|November 27, 2007
Gemcitabine in bladder cancerFadi El Karak, Aude Flechon
Journal of Biomedical Research|October 8, 2015
Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patientMarwan Ghosn, Alain Dagher, Fadi El-Karak
Expert Opinion on Pharmacotherapy|September 5, 2023
Pharmacotherapy developments in autophagy inhibitors for bladder cancerCeline Chaaya, Ghady Zgheib, Fadi El Karak
Immunotherapy|February 10, 2018
Where do the immune checkpoint inhibitors stand in the management of triple negative breast cancer?Elie El Rassy, Fadi El Karak, Marwan Ghosn
Springerplus|January 17, 2017
Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa regionFadi Farhat, Ahmad Othman, Fadi El Karak, et al.
Iranian Journal of Kidney Diseases|August 13, 2016
Onconephrology: What Should the Internist Know About Targeted Therapy in Solid Tumors?Elie El Rassy, Fadi El Karak, Jamale Rizkallah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Pleural metastasis in a patient with bladder cancerNathalie Bonnin, Fadi El Karak, Jean-Pierre Droz, et al.
Immunotherapy|June 13, 2019
The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?Elie Rassy, Ziad Bakouny, Tarek Assi, et al.
Clinics and Research in Hepatology and Gastroenterology|February 21, 2017
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysisElie El Rassy, Tarek Assi, Fadi El Karak, et al.
BMC Urology|June 19, 2009
Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experiencePierre Heudel, Fadi El Karak, Nabil Ismaili, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Expert Opinion on Pharmacotherapy|November 27, 2007
Gemcitabine in bladder cancerFadi El Karak, Aude Flechon
Journal of Biomedical Research|October 8, 2015
Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patientMarwan Ghosn, Alain Dagher, Fadi El-Karak
Expert Opinion on Pharmacotherapy|September 5, 2023
Pharmacotherapy developments in autophagy inhibitors for bladder cancerCeline Chaaya, Ghady Zgheib, Fadi El Karak
Immunotherapy|February 10, 2018
Where do the immune checkpoint inhibitors stand in the management of triple negative breast cancer?Elie El Rassy, Fadi El Karak, Marwan Ghosn
Springerplus|January 17, 2017
Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa regionFadi Farhat, Ahmad Othman, Fadi El Karak, et al.
Iranian Journal of Kidney Diseases|August 13, 2016
Onconephrology: What Should the Internist Know About Targeted Therapy in Solid Tumors?Elie El Rassy, Fadi El Karak, Jamale Rizkallah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Pleural metastasis in a patient with bladder cancerNathalie Bonnin, Fadi El Karak, Jean-Pierre Droz, et al.
Immunotherapy|June 13, 2019
The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?Elie Rassy, Ziad Bakouny, Tarek Assi, et al.
Clinics and Research in Hepatology and Gastroenterology|February 21, 2017
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysisElie El Rassy, Tarek Assi, Fadi El Karak, et al.
BMC Urology|June 19, 2009
Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experiencePierre Heudel, Fadi El Karak, Nabil Ismaili, et al.
Pageof 7